Quantum BioPharma Soars 10.38% on MS Imaging Breakthrough

On June 18, 2025, Quantum BioPharma's stock surged by 10.38% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Quantum BioPharma has made a significant breakthrough in its joint study with Massachusetts General Hospital (MGH). The first person with multiple sclerosis (MS) has been successfully scanned using a novel positron emission tomography (PET) imaging technique. This technique, developed by Dr. Pedro Brugarolas, aims to monitor myelin integrity and demyelination in MS patients. The study is evaluating the PET tracer [18F]3F4AP, which has shown promising results in previous animal and human studies, indicating its potential as a biomarker for monitoring changes in demyelination in response to remyelinating or neuroprotective drugs.

The PET scan was performed on a newly installed combined GE Signa PET-MR scanner at MGH, which allows for simultaneous acquisition of the PET imaging signal and MRI, improving spatial and temporal coregistration. This advancement not only enhances the accuracy of the imaging technique but also improves the patient experience by reducing the time needed to complete both scans. The study is still in its early stages, but the initial results are encouraging, suggesting that this novel biomarker and technique could lead to more accurate measurements of responses to drugs that prevent or promote demyelination.